Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344203 | 0.89 | MEN1 (0.38) | MAPTRAB9ANPC1MAPK1HSP90AA1 | |
| SCHEMBL3379154 | 0.88 | MAPT (0.38) | MAPTRAB9ANPC1MAPK1HSP90AA1 | |
| SCHEMBL3367001 | 0.83 | MAPT (0.44) | MAPTRAB9ANPC1MAPK1HSP90AA1 | |
| SCHEMBL14928319 | 0.79 | MAPT (0.43) | MAPTRAB9ANPC1CYP19A1CNR1 | |
| SCHEMBL14928241 | 0.77 | MAPT (0.43) | MAPTRAB9ANPC1CYP19A1MAPK1 | |
| SCHEMBL14928357 | 0.77 | MAPT (0.43) | MAPTRAB9ANPC1CYP19A1MAPK1 | |
| SCHEMBL14928601 | 0.76 | TRPC6 (0.36) | MAPTRAB9ANPC1CNR2ALDH1A1 | |
| SCHEMBL22165793 | 0.75 | HSP90AA1 (0.42) | MAPTMAPK1HSP90AA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7247518 | 0.74 | TP53 (0.44) | MAPTRAB9ANPC1CYP19A1ALDH1A1 | |
| SCHEMBL31378931 | 0.73 | HSP90AA1 (0.43) | MAPTRAB9AMAPK1HSP90AA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | MAPT 4186/4885RAB9A 2445/4885NPC1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.